MedTrace Logo

Predictors of HCC in Post-HCV Cirrhotic Patients After SVR

NCT07097870 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-08-05

No results posted yet for this study

Summary

This study aims to identify clinical and laboratory factors that predict the occurrence of hepatocellular carcinoma (HCC) in Egyptian cirrhotic patients after achieving a sustained virologic response (SVR) to hepatitis C virus (HCV) treatment. This is a retrospective, two-center, case-control study that will include 132 cases and 264 controls. Variables to be analyzed include demographics, liver disease status, metabolic comorbidities, lifestyle factors, medications, as well as laboratory parameters and non-invasive scoring systems.

Conditions

  • HCC - Hepatocellular Carcinoma

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Usama A Arafa, PhD · Faculty of Medicine, Sohag university

  • Ali M Hussein, PhD · Faculty of Medicine, Sohag university

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-31
Primary Completion
2025-09-30
Completion
2025-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07097870 on ClinicalTrials.gov